We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Geovax Labs Inc is us-based clinical-stage biotechnology company. Geovax Labs Inc is us-based clinical-stage biotechnology company.
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies...
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that...
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and...
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance...
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against...
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced...
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today...
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.08 | 3.27868852459 | 2.44 | 2.75 | 2.385 | 1114952 | 2.5432137 | CS |
4 | -0.1 | -3.81679389313 | 2.62 | 2.75 | 2.13 | 715418 | 2.40193069 | CS |
12 | 0.51 | 25.3731343284 | 2.01 | 3.88 | 1.75 | 1757415 | 2.84113355 | CS |
26 | -0.18 | -6.66666666667 | 2.7 | 11.18 | 1.6 | 3154422 | 5.17949865 | CS |
52 | -3.03 | -54.5945945946 | 5.55 | 11.18 | 1.0901 | 2261287 | 4.52567115 | CS |
156 | -50.88 | -95.2808988764 | 53.4 | 64.5 | 1.0901 | 3730627 | 25.31410439 | CS |
260 | -42.48 | -94.4 | 45 | 130.65 | 1.0901 | 3043121 | 32.35060095 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions